Neurology Clinical Trials Market Share Analysis Report, 2023-2032
The global neurology clinical trials market size was exhibited at USD 6.9 billion in 2022 and is projected to hit around USD 12.01 billion by 2032, growing at a CAGR of 5.7% during the forecast period 2023 to 2032.
Key Pointers:
Neurology Clinical Trials Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 7.29 Billion |
|
Market Size by 2032 |
USD 12.01 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of 5.7% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Phase, study design, indication, indication by study design, indication by phase |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
IQVIA; Novartis; Covance; Med pace; Charles River Laboratories; Syneous Health; Icon Plc.; GlaxoSmithKline; Aurora healthcare; Biogen |
This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.
Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.9 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. The adoption of similar initiatives in the future is expected to support market growth.
A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.
Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.
Phase Insights
The phase II clinical trials segment dominated the market for neurology clinical trials and held the largest revenue share of 46.9% in 2022. Based on phase the market is segmented into Phase I, Phase II, Phase III, and Phase IV.A growing number of industry-sponsored and non-industry-sponsored clinical trials in phase II, the complexity associated with phase II clinical trials, and the globalization of clinical trials are supporting the growth of the segment.
A significant number of phase I drugs have been approved in the past few years. For instance, the biotech company PharmaTher Holdings Ltd. stated in May 2021 that the U.S. FDA had approved its Investigational New Drug (IND) application to advance the company’s ketamine drug to phase II clinical trial, to study the safety, efficacy, and pharmacokinetics of the drug in Parkinson’s patients. Such approvals are further expected to boost segment growth.
Phase III is anticipated to register the fastest growth of 5.7% CAGR throughout the forecast period. This growth may be attributed to the fact that phase III clinical trials are the costliest and involve a large number of participants. The clinical trial market players are actively initiating phase III trials in order to understand the safety and potency of treatment. For instance, in April 2022, Pfizer stated that it intends to open clinical trial sites to conduct phase III trials of its investigational mini-dystrophin gene therapy used to treat Duchenne muscular dystrophy patients. Such initiatives by market players are likely to propel the segment's growth.
Indication Insights
The Huntington’s disease segment is anticipated to register the fastest growth rate of 6.1% throughout the forecast period. Based on indication, the market is segmented into epilepsy, Parkinson’s disease (PD), Huntington’s disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), muscle regeneration, and others. There is a high demand for newer medications as there is no available treatment for Huntington’s disease.
Most of the cases are hereditary or caused due to mutation. As of June 2022, only 222 studies were registered for HD, out of which, the majority of studies were in phases I and II, and only three studies were reported to be in phase IV. The low number of studies in phase IV and the relative lack of medication available for the diseases are expected to drive the demand for research, which is likely to have a positive impact on the market.
Epilepsy held the largest share of 21.19% in 2022. Epilepsy is one of the most common neurological diseases, with more than 65.0 million people worldwide affected by it according to the WHO. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. According to ClinicalTrials.gov, there are a total of 1,755 studies for epilepsy as of June 2022. The growing awareness regarding epilepsy and demand for advanced treatment for the condition is expected to drive the segment’s market.
Study Design Insights
The interventional segment led the market for neurology clinical trials and accounted for the largest revenue share of 96.14% in 2022. Based on the study design, the market is segmented into interventional, observational, and expanded access. The growth can be attributed to the fact that a large number of interventional studies for Central Nervous System (CNS) conditions are being conducted across the globe.
As of June 2022, there are above 23,000 interventional studies listed on ClinicalTrails.gov related to CNS conditions. For instance, an interventional study titled Feasibility of Acquiring Hyperpolarized Imaging in Patients with Primary CNS Lymphoma was in the recruiting stage in April 2022. All these factors support the segment market.
The observational segment is anticipated to witness a substantial expansion of 5.9% CAGR throughout the forecast period. In a variety of situations, such as post-marketing safety evaluations of drugs or when clinical trials are not feasible, observational studies are routinely used to evaluate treatment effects. Furthermore, as of June 2022, of the total CNS condition studies listed on ClinicalTrials.gov, more than 7,900 are observational.
For instance, an observational study titled "The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study" was completed in January 2022. The above-mentioned factors support the segment market.
Regional Insights
North America dominated the neurology clinical trials market and accounted for the largest revenue share of 47.18% in 2022. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials are driving the market for neurology clinical trials in the region. As the population ages and total life expectancy rises, dementia would become more common, with an estimated 10.9 million Americans aged 65 and older suffering from Alzheimer's disease or another dementia by 2032.
Asia Pacific is expected to expand with the fastest CAGR of 5.11% across the forecast. Asia Pacific is the fastest-growing market as many developed nations are investing in the Asia Pacific region. Recruitment for clinical trials is increasing in Asia as compared to North America and Europe. This is due to the large patient pool & low trial cost. Moreover, researchers are actively developing new neurological treatments in the region.
For instance, in February 2021, researchers at Jawaharlal Nehru Centre for Advanced Scientific Research in India developed a small molecule named TGR 63, which had the ability to disturb the mechanism through which neurons become nonfunctional in Alzheimer's disease. Such research activities are likely to contribute to the market growth of the region.
Some of the prominent players in the Neurology Clinical Trials Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Neurology Clinical Trials market.
By Phase
By Study Design
By Indication
By Indication by Study Design
By Indication by Phase
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Indication by Study Design
1.1.5. Indication by Phase
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Nova one advisor internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Neurology Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & growth prospect mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
3.3.1.2. Growing adoption of novel technologies in clinical research
3.3.1.3. Significant number of CROs providing neurology clinical research services
3.3.1.4. Increasing funding for neurological studies by public organizations
3.3.2. Market restraint analysis
3.3.2.1. High cost associated with neurology clinical studies.
3.3.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials.
3.4. Neurology Clinical Trials Market Analysis Tools
3.4.1. Porter’s Five Forces Analysis
3.4.2. PEST Analysis
3.5. COVID-19 Impact and Reformation Strategy
Chapter 4. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Neurology Clinical Trials Market: Phase Market Share Analysis, 2023 & 2032
4.2.1. Phase I
4.2.2. Phase II
4.2.3. Phase III
4.2.4. Phase IV
Chapter 5. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Neurology Clinical Trials Market: Study Design Market Share Analysis, 2023 & 2032
5.2.1. Interventional
5.2.2. Observational
5.2.3. Expanded Access
Chapter 6. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Definitions and Scope
6.2. Neurology Clinical Trials Market: Indication Market Share Analysis, 2023 & 2032
6.2.1. Epilepsy
6.2.2. Parkinson's Disease (PD)
6.2.3. Huntington's Disease
6.2.4. Stroke
6.2.5. Traumatic Brain Injury (TBI)
6.2.6. Amyotrophic Lateral Sclerosis (ALS)
6.2.7. Muscle regeneration
6.2.8. Others
Chapter 7. Neurology Clinical Trials Market: Indication By Study Design Estimates & Trend Analysis
7.1. Definitions and Scope
7.2. Neurology Clinical Trials Market: Indication By Study Design Market Share Analysis, 2023 & 2032
7.2.1. Epilepsy
7.2.1.1. Interventional
7.2.1.2. Observational
7.2.1.3. Expanded Access
7.2.2. Parkinson's Disease (PD)
7.2.2.1. Interventional
7.2.2.2. Observational
7.2.2.3. Expanded Access
7.2.3. Huntington's Disease
7.2.3.1. Interventional
7.2.3.2. Observational
7.2.3.3. Expanded Access
7.2.4. Stroke
7.2.4.1. Interventional
7.2.4.2. Observational
7.2.4.3. Expanded Access
7.2.5. Traumatic Brain Injury (TBI)
7.2.5.1. Interventional
7.2.5.2. Observational
7.2.5.3. Expanded Access
7.2.6. Amyotrophic Lateral Sclerosis (ALS)
7.2.6.1. Interventional
7.2.6.2. Observational
7.2.6.3. Expanded Access
7.2.7. Muscle regeneration
7.2.7.1. Interventional
7.2.7.2. Observational
7.2.7.3. Expanded Access
7.2.8. Others
7.2.8.1. Interventional
7.2.8.2. Observational
7.2.8.3. Expanded Access
Chapter 8. Neurology Clinical Trials Market: Indication By Phase Estimates & Trend Analysis
8.1. Definitions and Scope
8.2. Neurology Clinical Trials Market: Indication By Phase Market Share Analysis, 2023 & 2032
8.2.1. Epilepsy
8.2.1.1. Phase I
8.2.1.2. Phase II
8.2.1.3. Phase III
8.2.1.4. Phase IV
8.2.2. Parkinson's Disease (PD)
8.2.2.1. Phase I
8.2.2.2. Phase II
8.2.2.3. Phase III
8.2.2.4. Phase IV
8.2.3. Huntington's Disease
8.2.3.1. Phase I
8.2.3.2. Phase II
8.2.3.3. Phase III
8.2.3.4. Phase IV
8.2.4. Stroke
8.2.4.1. Phase I
8.2.4.2. Phase II
8.2.4.3. Phase III
8.2.4.4. Phase IV
8.2.5. Traumatic Brain Injury (TBI)
8.2.5.1. Phase I
8.2.5.2. Phase II
8.2.5.3. Phase III
8.2.5.4. Phase IV
8.2.6. Amyotrophic Lateral Sclerosis (ALS)
8.2.6.1. Phase I
8.2.6.2. Phase II
8.2.6.3. Phase III
8.2.6.4. Phase IV
8.2.7. Muscle regeneration
8.2.7.1. Phase I
8.2.7.2. Phase II
8.2.7.3. Phase III
8.2.7.4. Phase IV
8.2.8. Others
8.2.8.1. Phase I
8.2.8.2. Phase II
8.2.8.3. Phase III
8.2.8.4. Phase IV
Chapter 9. Neurology Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. Regional market share analysis, 2023 & 2032
9.2. North America
9.2.1. U.S.
9.2.1.1. U.S. market estimates and forecast, 2020-2032
9.2.2. Canada
9.2.2.1. Canada market estimates and forecast, 2020-2032
9.3. Europe
9.3.1. U.K.
9.3.1.1. U.K. market estimates and forecast, 2020-2032
9.3.2. Germany
9.3.2.1. Germany market estimates and forecast, 2020-2032
9.3.3. France
9.3.3.1. France market estimates and forecast, 2020-2032
9.3.4. Italy
9.3.4.1. Italy market estimates and forecast, 2020-2032
9.3.5. Spain
9.3.5.1. Spain market estimates and forecast, 2020-2032
9.4. Asia Pacific
9.4.1. Japan
9.4.1.1. Japan market estimates and forecast, 2020-2032
9.4.2. China
9.4.2.1. China market estimates and forecast, 2020-2032
9.4.3. India
9.4.3.1. India market estimates and forecast, 2020-2032
9.4.4. Australia
9.4.4.1. Australia market estimates and forecast, 2020-2032
9.4.5. South Korea
9.4.5.1. South Korea market estimates and forecast, 2020-2032
9.5. Latin America
9.5.1. Brazil
9.5.1.1. Brazil market estimates and forecast, 2020-2032
9.5.2. Mexico
9.5.2.1. Mexico market estimates and forecast, 2020-2032
9.5.3. Argentina
9.5.3.1. Argentina market estimates and forecast, 2020-2032
9.5.4. Colombia
9.5.4.1. Colombia market estimates and forecast, 2020-2032
9.6. MEA
9.6.1. South Africa
9.6.1.1. South Africa market estimates and forecast, 2020-2032
9.6.2. Saudi Arabia
9.6.2.1. Saudi Arabia market estimates and forecast, 2020-2032
9.6.3. UAE
9.6.3.1. UAE market estimates and forecast, 2020-2032
Chapter 10. Competitive Landscape
10.1. Market Share Analysis
10.2. Participant Categorization
10.3. Recent Development and Impact Analysis
Chapter 11. Company Profiles
11.1. Company Overview
11.2. Financial Performance
11.3. Strategic Initiatives
11.3.1. Expansions
11.3.2. Partnerships and Collaborations
11.3.3. Acquisitions
11.3.3.1. Novartis
11.3.3.2. Covance
11.3.3.3. Med pace
11.3.3.4. Charles River Laboratories
11.3.3.5. Syneous Health
11.3.3.6. Icon Plc
11.3.3.7. GlaxoSmithKline
11.3.3.8. Aurora healthcare
11.3.3.9. Biogen
11.3.3.10. IQVIA
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers